Rare disease drugmakers would retain their special status when pursuing treatments especially for children under legislation scheduled to be marked up by a Senate panel next week.
The legislation aims to head off future lawsuits like the one Catalyst Pharmaceuticals Inc. won last year, granting them exclusive rights to market a drug to treat a rare disease.
Sen. Tammy Baldwin’s (D-Wis.) Retaining Access and Restoring Exclusivity Act, or RARE, Act (S. 1214) is one of a package of drug pricing bills the Senate Health, Education, Labor and Pensions will consider May 2. Baldwin’s bill aims to solidify incentives that ...